Header Logo

Connection

Yehuda Handelsman to Diabetes Mellitus, Type 2

Back to Details
This is a "connection" page, showing publications Yehuda Handelsman has written about Diabetes Mellitus, Type 2.
Yehuda Handelsman
Connection Strength
14.718
Diabetes Mellitus, Type 2
  1. Evidence-Based Positioning of Sodium-Glucose Co-transporter?2 Inhibitors and Glucagon-Like Peptide?1 Receptor Agonists in the Management of Chronic Kidney Disease with Type?2 Diabetes and Overweight or Obesity: A Systematic Literature Review. Adv Ther. 2026 May; 43(5):1983-2000.
    View in: PubMed
    Score: 0.750
  2. Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2023 07 11; 82(2):161-170.
    View in: PubMed
    Score: 0.622
  3. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2022 02; 36(2):108101.
    View in: PubMed
    Score: 0.557
  4. Sodium-glucose cotransporter 2 inhibitors for macroalbuminuria: A new indication. J Diabetes. 2020 Jan; 12(1):8-9.
    View in: PubMed
    Score: 0.483
  5. Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine. Adv Ther. 2019 12; 36(12):3321-3339.
    View in: PubMed
    Score: 0.481
  6. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes. Adv Ther. 2019 10; 36(10):2567-2586.
    View in: PubMed
    Score: 0.475
  7. Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2019 04; 21(4):883-892.
    View in: PubMed
    Score: 0.455
  8. Notes from the world congress on insulin resistance, diabetes, and cardiovascular disease. J Diabetes. 2019 Apr; 11(4):258-260.
    View in: PubMed
    Score: 0.455
  9. Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes. J Diabetes Complications. 2019 03; 33(3):236-242.
    View in: PubMed
    Score: 0.452
  10. Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists. J Manag Care Spec Pharm. 2018 Sep; 24(9-a Suppl):S14-S29.
    View in: PubMed
    Score: 0.444
  11. World congress on insulin resistance, diabetes and cardiovascular disease. J Diabetes. 2018 Oct; 10(10):776-777.
    View in: PubMed
    Score: 0.439
  12. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Curr Med Res Opin. 2017 10; 33(10):1861-1868.
    View in: PubMed
    Score: 0.409
  13. Lorcaserin treatment allows for decreased number needed to treat for weight and glycemic parameters in week 12 responders with =5% weight loss. Postgrad Med. 2016 Nov; 128(8):740-746.
    View in: PubMed
    Score: 0.390
  14. Approaches to treatment 2: Comparison of American Association of Clinical Endocrinologists (AACE) and American Diabetes Association (ADA) type 2 diabetes treatment guidelines. J Diabetes. 2016 Jan; 8(1):4-6.
    View in: PubMed
    Score: 0.367
  15. SGLT-2 INHIBITION ADDED TO GLP-1 AGONIST THERAPY FOR TYPE 2 DIABETES: WHAT IS THE BENEFIT? Endocr Pract. 2015 Dec; 21(12):1442-4.
    View in: PubMed
    Score: 0.364
  16. POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS. Endocr Pract. 2015 Sep; 21(9):1054-65.
    View in: PubMed
    Score: 0.357
  17. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes Care. 2014 Oct; 37(10):2723-30.
    View in: PubMed
    Score: 0.334
  18. Lessons from glargine trials: what is the goal fasting glucose with basal insulin? J Diabetes. 2014 Jul; 6(4):271-3.
    View in: PubMed
    Score: 0.328
  19. Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials. Endocr Pract. 2014 Apr; 20(4):285-92.
    View in: PubMed
    Score: 0.327
  20. Is combination therapy an effective way of reaching lipid goals in type 2 diabetes mellitus? Expert Rev Clin Pharmacol. 2012 Jan; 5(1):43-54.
    View in: PubMed
    Score: 0.280
  21. Overcoming obstacles in risk factor management in type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2011 Aug; 13(8):613-20.
    View in: PubMed
    Score: 0.271
  22. Role of bile acid sequestrants in the treatment of type 2 diabetes. Diabetes Care. 2011 May; 34 Suppl 2:S244-50.
    View in: PubMed
    Score: 0.267
  23. The role of bile acid sequestrants in the management of type 2 diabetes mellitus: summary and future directions. Metab Syndr Relat Disord. 2010 Dec; 8 Suppl 1:S23-4.
    View in: PubMed
    Score: 0.260
  24. Insulin treatment of Type 2 diabetes: a clinical perspective. J Diabetes. 2010 Jun; 2(2):65-6.
    View in: PubMed
    Score: 0.248
  25. The use of the bile acid sequestrant colesevelam HCl in patients with type 2 diabetes mellitus: for glucose and lipid control. Introduction. Postgrad Med. 2009 May; 121(3 Suppl 1):5-6.
    View in: PubMed
    Score: 0.233
  26. The role of colesevelam HCl in type 2 diabetes mellitus therapy. Postgrad Med. 2009 May; 121(3 Suppl 1):19-24.
    View in: PubMed
    Score: 0.233
  27. Pharmacologic treatment options for prediabetes. Nat Clin Pract Endocrinol Metab. 2008 Jul; 4(7):380-1.
    View in: PubMed
    Score: 0.218
  28. Treating diabetes with incretin hormones - clinical experience. Pediatr Endocrinol Rev. 2008 Jun; 5(4):897-903.
    View in: PubMed
    Score: 0.218
  29. Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial. BMJ. 2024 10 15; 387:e080122.
    View in: PubMed
    Score: 0.170
  30. Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristone. BMJ Open. 2024 07 16; 14(7):e081121.
    View in: PubMed
    Score: 0.167
  31. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Metabolism. 2024 Oct; 159:155931.
    View in: PubMed
    Score: 0.166
  32. Cardio-renal-metabolic disease in primary care setting. Diabetes Metab Res Rev. 2024 Mar; 40(3):e3755.
    View in: PubMed
    Score: 0.160
  33. Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. Circulation. 2020 09 22; 142(12):1205-1218.
    View in: PubMed
    Score: 0.128
  34. Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure. Eur J Heart Fail. 2020 04; 22(4):604-617.
    View in: PubMed
    Score: 0.122
  35. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY. Endocr Pract. 2020 01; 26(1):107-139.
    View in: PubMed
    Score: 0.122
  36. Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study. Diabetologia. 2019 06; 62(6):948-958.
    View in: PubMed
    Score: 0.116
  37. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY. Endocr Pract. 2019 01; 25(1):69-100.
    View in: PubMed
    Score: 0.114
  38. EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES. Endocr Pract. 2019 Feb; 25(2):144-155.
    View in: PubMed
    Score: 0.112
  39. DYSGLYCEMIA-BASED CHRONIC DISEASE: AN AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS POSITION STATEMENT. Endocr Pract. 2018 Nov; 24(11):995-1011.
    View in: PubMed
    Score: 0.112
  40. Burden of Illness in Type 2 Diabetes Mellitus. J Manag Care Spec Pharm. 2018 Sep; 24(9-a Suppl):S5-S13.
    View in: PubMed
    Score: 0.111
  41. Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications. J Manag Care Spec Pharm. 2018 Sep; 24(9-a Suppl):S42-S52.
    View in: PubMed
    Score: 0.111
  42. Health-Related Quality of Life Assessments with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus. J Manag Care Spec Pharm. 2018 Sep; 24(9-a Suppl):S30-S41.
    View in: PubMed
    Score: 0.111
  43. Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100?U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes. Diabetes Obes Metab. 2018 12; 20(12):2821-2829.
    View in: PubMed
    Score: 0.111
  44. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY 2018 POSITION STATEMENT ON INTEGRATION OF INSULIN PUMPS AND CONTINUOUS GLUCOSE MONITORING IN PATIENTS WITH DIABETES MELLITUS. Endocr Pract. 2018 Mar; 24(3):302-308.
    View in: PubMed
    Score: 0.107
  45. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY. Endocr Pract. 2018 01; 24(1):91-120.
    View in: PubMed
    Score: 0.106
  46. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. JAMA. 2017 Jul 04; 318(1):45-56.
    View in: PubMed
    Score: 0.102
  47. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY. Endocr Pract. 2017 02; 23(2):207-238.
    View in: PubMed
    Score: 0.099
  48. Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes. 2017 02; 66(2):241-255.
    View in: PubMed
    Score: 0.099
  49. CONTINUOUS GLUCOSE MONITORING: A CONSENSUS CONFERENCE OF THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY. Endocr Pract. 2016 Aug; 22(8):1008-21.
    View in: PubMed
    Score: 0.095
  50. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY 2016 OUTPATIENT GLUCOSE MONITORING CONSENSUS STATEMENT. Endocr Pract. 2016 Feb; 22(2):231-61.
    View in: PubMed
    Score: 0.093
  51. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. Endocr Pract. 2016 Jan; 22(1):84-113.
    View in: PubMed
    Score: 0.092
  52. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2015 EXECUTIVE SUMMARY. Endocr Pract. 2015 Dec; 21(12):1403-14.
    View in: PubMed
    Score: 0.092
  53. Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-na?ve patients with type 2 diabetes. Diabetes Obes Metab. 2014 Sep; 16(9):869-72.
    View in: PubMed
    Score: 0.081
  54. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab. 2014 Jul; 16(7):636-44.
    View in: PubMed
    Score: 0.081
  55. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type?2 diabetes: a 2-year randomized, treat-to-target trial. Diabet Med. 2013 Nov; 30(11):1298-304.
    View in: PubMed
    Score: 0.079
  56. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013 Mar-Apr; 19(2):327-36.
    View in: PubMed
    Score: 0.076
  57. The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations. Endocr Pract. 2013 Jan-Feb; 19(1):100-6.
    View in: PubMed
    Score: 0.075
  58. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012 Dec; 35(12):2464-71.
    View in: PubMed
    Score: 0.074
  59. Initial combination therapy with metformin plus colesevelam in drug-na?ve Hispanic patients with early type 2 diabetes. Postgrad Med. 2012 Jul; 124(4):7-13.
    View in: PubMed
    Score: 0.072
  60. Comprehensive diabetes cardiovascular treatment = sugar + blood pressure + lipids. J Diabetes. 2011 Dec; 3(4):257-60.
    View in: PubMed
    Score: 0.070
  61. The Avandia debate: an unhappy conclusion. J Diabetes. 2010 Dec; 2(4):221-2.
    View in: PubMed
    Score: 0.065
  62. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. Endocr Pract. 2010 Jul-Aug; 16(4):629-40.
    View in: PubMed
    Score: 0.063
  63. Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes Metab. 2010 May; 12(5):384-92.
    View in: PubMed
    Score: 0.062
  64. Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. Endocr Pract. 2010 Jan-Feb; 16(1):53-63.
    View in: PubMed
    Score: 0.061
  65. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009 Sep-Oct; 15(6):540-59.
    View in: PubMed
    Score: 0.060
  66. Metabolic syndrome pathophysiology and clinical presentation. Toxicol Pathol. 2009 Jan; 37(1):18-20.
    View in: PubMed
    Score: 0.057
  67. Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. Endocr Pract. 2007 May-Jun; 13(3):260-8.
    View in: PubMed
    Score: 0.051
  68. Use of finerenone in patients with chronic kidney disease at high risk of heart failure. Metabolism. 2025 Aug; 169:156297.
    View in: PubMed
    Score: 0.044
  69. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Endocr Pract. 2017 Apr; 23(Suppl 2):1-87.
    View in: PubMed
    Score: 0.025
  70. TRANSCULTURALIZATION RECOMMENDATIONS FOR DEVELOPING LATIN AMERICAN CLINICAL PRACTICE ALGORITHMS IN ENDOCRINOLOGY--PROCEEDINGS OF THE 2015 PAN-AMERICAN WORKSHOP BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY. Endocr Pract. 2016 Apr; 22(4):476-501.
    View in: PubMed
    Score: 0.023
  71. The CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome. J Am Coll Cardiol. 2015 Sep 01; 66(9):1050-67.
    View in: PubMed
    Score: 0.023
  72. Practical perspectives on the management of overweight and obesity. Am J Manag Care. 2014 Mar; 20(3 Suppl):S64-75.
    View in: PubMed
    Score: 0.020
  73. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007 May-Jun; 13 Suppl 1:1-68.
    View in: PubMed
    Score: 0.013
  74. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003 May-Jun; 9(3):237-52.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.